Briefing
HERizon-Breast: a ctDNA-guided adaptive study of sequential anti-HER2 therapy
Phase 2 ctDNA-guided study in unresectable locally advanced or metastatic HER2-positive breast cancer. The registry primary outcome is the proportion who maintain a complete response and a molecular complete response. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting